Pfizer on Wednesday revealed that it raised the listing value of a course of Paxlovid—its lifesaving antiviral drug used to cut back the chance of extreme COVID-19 in these most weak—to just about $1,400, greater than double the roughly $530 the US authorities has paid for the therapy within the emergency section of the pandemic.
Pfizer CEO Albert Bourla had famous in an investor name firstly of the week that the corporate would improve the value of Paxlovid because it strikes from authorities distribution to the industrial market on the finish of this 12 months. However, he didn’t announce the brand new listing value then. As an alternative, the corporate revealed the greater than twofold improve in a letter to pharmacies and clinics dated Wednesday. The Wall Avenue Journal was the primary to report the listing value of $1,390 after viewing the letter.
A Pfizer spokesperson advised the Journal that “pricing for Paxlovid is predicated on the worth it gives to sufferers, suppliers, and well being care techniques as a consequence of its vital position in serving to scale back COVID-19-related hospitalizations and deaths.”
Learn 5 remaining paragraphs | Feedback